Liver Cancer
Copyright ©The Author(s) 2004.
World J Gastroenterol. Jun 1, 2004; 10(11): 1547-1550
Published online Jun 1, 2004. doi: 10.3748/wjg.v10.i11.1547
Table 1 Demographic and clinical data of female and male patients with HCC at initial diagnosis
CharacteristicsFemale (n = 39)Male (n = 260)P
Age (yr)56.4 ± 15.252.6 ± 13.2NS
Underlying cirrhosis (+:-)36:3251:9NS
Viral hepatitis marker
HBsAg (+:-)18:21147:113NS
Anti-HCV (+:-)5:3423:237NS
Heavy alcohol consumption (+:-)3:3683:1770.002
Mean AFP (IU/mL)48435.4 ± 105231.640221.9 ± 89147.9NS
Biochemical liver function tests
Total bilirubin (mg/dL)1.5 ± 1.23.1 ± 2.30.03
Alkaline phosphatase (IU/L)451.6 ± 277.3529.3 ± 375.0NS
AST (IU/L)128.4 ± 133.2154.3 ± 135.2NS
ALT (IU/L)62.7 ± 52.687.6 ± 97.5NS
Albumin (g/dL)3.6 ± 0.73.4 ± 0.7NS
Prothrombin time (sec)14.5 ± 2.815.1 ± 9.3NS
Table 2 Clinicopathologic data of female and male patients with HCC at initial diagnosis
CharacteristicsFemale (n = 39)Male (n = 260)P
Mean tumor size (cm)8.1 ± 3.911.6 ± 4.50.02
Tumor size
≤5 cm:> 5 cm9:3030:2300.04
Gross appearance of HCC
Nodular:Multinodular:Massive:Diffuse12:10:14:330:52:115:630.01
Tumor cell differentiation
Well:Moderately:Poorly3:5:411:66:32NS
Okuda’ s staging (I:II:III)13:23:343:180:370.04
Portal or hepatic vein invasion (+:-)6:3384:1760.03
Extrahepatic metastasis (+:-)5:3437:223NS
Ruptured HCC (+:-)1:3829:231NS
Therapy for HCC (+:-)22:17105:155NS
Modality of therapy
Surgical resection (+:-)9:3027:2330.02
Chemoembolization (+:-)13:2643:2170.01
Systemic chemotherapy (+:-)0:3931:2290.02
Table 3 Independent predictors influencing survival in HCC
VariablesRegression coefficient (95% CI)P value1
AFP (> 400 IU/mL)1.67 (1.03-2.71)0.037
Portal or hepatic vein invasion1.73 (1.04-2.89)0.035
Extrahepatic metastasis2.37 (1.30-4.37)0.005
No therapy2.87 (1.63-5.04)0.0002